Practical Geriatrics ›› 2022, Vol. 36 ›› Issue (5): 528-531.doi: 10.3969/j.issn.1003-9198.2022.05.024
Previous Articles Next Articles
Received:2021-07-16
Online:2022-05-20
Published:2022-05-27
CLC Number:
| [1] SIDDHARTH J,CHAKRABARTI A,PANNÉREC A,et al.Aging and sarcopenia associate with specific interactions between gut microbes, serum biomarkers and host physiology in rats[J]. Aging: Albany NY, 2017,9(7):1698-1714. [2] NATIONS U. World population prospects[M]. New York: United Nations Publications,2017: 1-11. [3] SZLEJF C, SUEMOTO C K, JANOVSKY C C P S,et al.Thyroid function and sarcopenia: results from the ELSA-Brasil Study[J]. J Am Geriatr Soc, 2020, 68(7): 1545-1553. [4] ZHAO M, ZHOU X, YUAN C,et al.Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study[J]. Sci Rep,2020,10(1):16093. [5] BATSIS J A, VILLAREAL D T.Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies[J]. Nat Rev Endocrinol,2018, 14(9): 513-537. [6] PARIS M T, BELL K E, MOURTZAKIS M.Myokines and adipokines in sarcopenia: understanding cross-talk between skeletal muscle and adipose tissue and the role of exercise[J]. Curr Opin Pharmacol, 2020,52(6):61-66. [7] JODEIRI FARSHBAF M, ALVIÑA K.Multiple roles in neuroprotection for the exercise derived myokine irisin[J]. Front Aging Neurosci,2021,13:649929. [8] COLAIANNI G, SANESI L, STORLINO G, et al. Irisin and bone: from preclinical studies to the evaluation of its circulating levels in different populations of human subjects[J]. Cells, 2019, 8(5): 451. [9] SCHUMACHER M A, CHINNAM N, OHASHI T,et al.The structure of irisin reveals a novel intersubunit beta-sheet fibronectin type III (FNIII) dimer: implications for receptor activation[J]. J Biol Chem,2013,288(47):33738-33744. [10] NIE Y,LIU D.N-Glycosylation is required for FDNC5 stabilization and irisin secretion[J]. Biochem,2017,474(18):3167-3177. [11] ROCA-RIVADA A,CASTELA O C,SENIN LL,et al.FNDC5/irisin is not only a myokine but also an adipokine[J]. PLoS One,2013,8(9):60563. [12] TIANO J P,SPRINGER D A, RANE S G.SMAD3 negatively regulates serum irisin and skeletal muscle FNDC5 and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) during exercise[J]. J Biol Chem,2015,290(18):7671-7684. [13] VARELA-RODRÍGUEZ B M,PENA-BELLO L,JUIZ-VALIÑA P, et al. FNDC5 expression and circulating irisin levels are modified by diet and hormonal conditions in hypothalamus, adipose tissue and muscle[J]. Sci Rep, 2016, 6: 29898. [14] REZA M M,SUBRAMANIYAM N,SIM C M,et al.Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy[J]. Nature,2017,8(1):1104. [15] ZHANG D,XIE T,LEUNG P S.Irisin ameliorates glucolipotoxicity-associated beta-cell dysfunction and apoptosis via AMPK signaling and anti-inflammatory actions[J]. Cell Physiol Biochem,2018,51(2):924-937. [16] HUH J Y, DINCER F,MESFUM E,et al.Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans[J]. Int J Obes,2014,38(12):1538-1544. [17] VAUGHAN R A, GANNON N P,BARBERENA M A,et al.Characterizationof the metabolic effects of irisin on skeletal muscle in vitro[J]. Diabetes Obes Metab,2014,16(8):711-718. [18] CHOI Y K,KIM M K,BAE K H,et al. Serum irisin levels in new-onset type 2 diabetes[J]. Diabetes Res Clin Pract, 2013, 100(1): 96-101. [19] KIM H J,SO B,CHOI M,et al. Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans[J]. Exp Gerontol,2015,70:11-17. [20] AMENGUAL J,GARCÍA-CARRIZO F J,ARREGUÍN A,et al.Retinoic acid increases fatty acid oxidation and irisin expression in skeletal muscle cells and impacts irisin in vivo[J]. Cell Physiol Biochem, 2018, 46(1): 187-202. [21] KIM H, WRANN C D,JEDRYCHOWSKI M,et al.Irisin mediates effects on bone and fat via alphaV integrin receptors[J]. Cell,2018,175(7):1756-1768. [22] 陈雪飞,方明,张靓.新的肌肉因子:Meteorin样因子[J]. 生理科学进展, 2019,50(4):289-292. [23] ZHENG S L,LI Z Y,SONG J, et al. Metrnl: a secreted protein with new emerging functions[J].Acta Pharmacol Sin, 2016, 37(5): 571-579. [24] LI Z Y,ZHENG S L,WANG P,et al.Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression[J]. CNS Neurosci Ther,2014,20(4): 344-354. [25] NISHINO J,YAMASHITA K,HASHIGUCHI H,et al.Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension[J]. EMBO J,2004,23(9):1998-2008. [26] USHACH I,BURKHARDT A M,MARTINEZ C, et al.METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages[J]. Clin Immunol,2015,156(2):119-127. [27] LI Z Y, SONG J, ZHENG S L,et al. Adipocyte metrnl antagonizes insulin resistance through PPARγ signaling[J]. Diabetes, 2015,64(12): 4011-4022. [28] USHACH I,BURKHARDT A M,MARTINEZ C,et al.METEORIN-LIKE isacytokine associated with barrier tissues and alternatively activated macrophages[J]. Clin Immunol,2015,156(2): 119-127. [29] BAHT G S, BAREJA A, LEE D E, et al.Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism[J]. Nat Metab, 2020,2(3):278-289. [30] JORGENSEN J R,FRANSSON A,FJORD-LARSEN L,et al.Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo[J]. Exp Neurol,2012,233(1):172-181. [31] LEE J O, BYUN W S, KANG M J, et al. The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKα2[J]. FEBS J,2020,28(10)7:2087-2104. |
| [1] | . [J]. Practical Geriatrics, 2024, 38(10): 1064-1065. |
| [2] | . [J]. Practical Geriatrics, 2024, 38(10): 1074-1077. |
| [3] | . [J]. Practical Geriatrics, 2023, 37(10): 1056-1058. |
| [4] | . [J]. Practical Geriatrics, 2023, 37(1): 5-8. |
| [5] | BO Ying-ying, MO Yong-zhen, OUYANG Xiao-jun, SHEN Xiao-xing, ZHU Hai-qiong, WANG Jie, LIU Xiao-qin, LIU Mei-li, LIU Huan, XU Jia-ren. Analysis of influencing factors of dysphagia in hospitalized elderly patients with sarcopenia [J]. Practical Geriatrics, 2022, 36(6): 632-635. |
| [6] | LI Wen-yan, LU Na, RUAN Hai-hui, LIU Jin, YUAN Rong-jing, WANG Ye-tong, SU Qing-ling, WANG Yan-hong. Prevalence and risk factors of sarcopenic dysphagia in elderly: a systematic review [J]. Practical Geriatrics, 2022, 36(4): 390-394. |
| [7] | . [J]. Practical Geriatrics, 2021, 35(12): 1309-1312. |
| [8] | . [J]. Practical Geriatrics, 2021, 35(10): 1080-1083. |
| [9] | . [J]. Practical Geriatrics, 2021, 35(7): 758-761. |
| [10] | ZHU Qian-qian, MEI Ke-wen, CHEN shu. Effects on muscle function and fall efficacy in the elderly sarcopenia patients with high risk of falling by sitting exercise therapy [J]. Practical Geriatrics, 2021, 35(7): 773-775. |
| [11] | CHEN Ying, ZHAO Mei. Clinical efficacy of photon therapy combined with functional exercise in elderly patients with end-stage renal disease [J]. Practical Geriatrics, 2021, 35(7): 776-779. |
| [12] | GUO Ming-Xian, GUO Feng, GAO Li, ZHANG Gui-Gong, ZHANG Xiu-Fen, LV Shu-Ping. Epidemiological survey and analysis about senile dementia among the elderly living in groups in Xi'an [J]. Practical Geriatrics, 2010, 24(2): 125-127. |
| [13] | . [J]. Practical Geriatrics, 2024, 38(7): 743-747. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|
